Organisation paid for research Program year 2025 Source: CMS Open Payments

Paddington Testing Co Inc

Neither a doctor nor a teaching hospital

Research payments

$480,222

234 payments

Through program year 2025, Paddington Testing Co Inc is reported as receiving $480,222 in research payments, across 234 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$118,218	97
2024	Research	$84,731	41
2023	Research	$65,837	6
2022	Research	$20,145	13
2021	Research	$33,657	12
2020	Research	$77,347	30
2019	Research	$80,286	35

Breakdown

Who paid Research payments · program years 2019–2025

Amgen Inc. $145,310 6 payments
Incyte Corporation $134,162 143 payments
AbbVie, Inc. $82,850 43 payments
Pfizer Inc. $64,287 23 payments
Galderma Laboratories, L.P. $28,601 11 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $8,727 3 payments
Vanda Pharmaceuticals Inc. $6,250 2 payments
Galderma Research & Development, LLC $5,829 1 payment
Boehringer Ingelheim Pharma GmbH & Co.KG $4,206 2 payments

Studies the money was for Research payments · program years 2019–2025

Jak1 Dupilumab Comparator Study $63,936 17 payments
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream $55,130 29 payments
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) $54,981 1 payment
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) $49,797 18 payments
P3 AD Adolescent Mono $23,800 1 payment
P3 AD Adult Combo TCS $23,800 1 payment
Efficacy Safety Study of Apremilast in Subjects With Moderate to Severe Genital Psoriasis (PSOR-025) $21,404 1 payment
An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis (DISCREET) $21,325 2 payments
M15-997 $20,358 8 payments
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis $20,351 9 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.